GlassScriptPhysician profile
Joseph W Burke
NPI 1497799308
$1,540.82
in general payments reported to CMS, 2019-2025
26 companies · $31.48 in 2025
The $31.48 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $833 · 2020: $147 · 2021: $137 · 2022: $64.77 · 2023: $113 · 2024: $214 · 2025: $31.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $359.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $237.37 | 2019-2020 | |
| Stryker Corporation | $191.65 | 2024 | Salvation |
| Astrazeneca Pharmaceuticals LP | $148.41 | 2019-2020 | |
| Medtronic Vascular, INC. | $98.86 | 2019 | |
| Abbvie INC. | $79.58 | 2021-2024 | Vraylar |
| Amgen INC. | $77.97 | 2019-2025 | Evenity, Prolia |
| Amarin Pharma, INC. | $66.94 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $59.17 | 2023 | |
| Daiichi Sankyo INC. | $51.48 | 2019 | |
| Glaxosmithkline, LLC. | $51.24 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.50 | 2019-2021 | |
| Abbott Laboratories | $44.10 | 2022-2023 | Proclaim |
| Lilly USA, LLC | $41.04 | 2019-2021 | |
| Allergan, INC. | $39.96 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.07 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $32.61 | 2019 | |
| Novartis Pharmaceuticals Corporation | $31.36 | 2019-2021 | |
| Genentech USA, INC. | $30.22 | 2019 | |
| Sanofi Pasteur INC. | $29.13 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.09 | 2019 | |
| Merck Sharp & Dohme LLC | $25.46 | 2019-2020 | |
| Bioventus LLC | $24.97 | 2019 | |
| Janssen Pharmaceuticals, INC | $23.82 | 2021 | |
| Astellas Pharma US INC | $17.64 | 2021 | |
| Medtronic, INC. | $14.54 | 2023 | Intellis Adaptivestim |
| Althera Pharmaceuticals LLC | $12.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Burke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.